secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001493152-23-034740
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech enters amended research agreement with Roswell Park for Ampligen® studies
--------------------------------------------------------------------------------

- Agreement covers three clinical trials: melanoma, prostate cancer, triple-negative breast cancer.
- AIM will supply Ampligen® to Roswell Park for research projects at no cost.
- Term is three years from September 20, 2023, or until completion of research.
- Research may be funded by external entities (NIH, DOD, foundations); no financial terms disclosed.
- AIM retains ownership of Ampligen® and pre-existing IP; jointly developed inventions are shared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/0001493152-23-034740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-034740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer